73 related articles for article (PubMed ID: 23706758)
1. Individualising treatment for older people with diabetes.
Morley JE; Sinclair A
Lancet; 2013 Aug; 382(9890):378-380. PubMed ID: 23706758
[No Abstract] [Full Text] [Related]
2. [Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
J Pharm Belg; 2009 Jun; (2):64-6. PubMed ID: 19739530
[No Abstract] [Full Text] [Related]
3. [Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].
Ahrén B
Lakartidningen; 2007 Dec; 104(49-50):3763-4. PubMed ID: 18214322
[No Abstract] [Full Text] [Related]
4. Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193-203.
Carr RD; Katzeff HL; Alexander CM; Berger JP; Xu SS; Thornberry N
Diabetes Obes Metab; 2012 Apr; 14(4):383-4. PubMed ID: 22390829
[No Abstract] [Full Text] [Related]
5. The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
Hassoun AA; Al-Arouj M; Ibrahim M
Curr Med Res Opin; 2017 Jan; 33(1):161-167. PubMed ID: 27684469
[TBL] [Abstract][Full Text] [Related]
6. [Vildagliptin (Galvus) and fixed combination vildagliptine-metformin (Eucreas) in the treatment of type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2009 Mar; 64(3):161-7. PubMed ID: 19418936
[TBL] [Abstract][Full Text] [Related]
7. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
Forst T; Dworak M; Berndt-Zipfel C; Löffler A; Klamp I; Mitry M; Pfützner A
Diabetes Obes Metab; 2013 Jun; 15(6):576-9. PubMed ID: 23384119
[TBL] [Abstract][Full Text] [Related]
8. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
[TBL] [Abstract][Full Text] [Related]
9. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
10. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.
Schweizer A; Couturier A; Foley JE; Dejager S
Diabet Med; 2007 Sep; 24(9):955-61. PubMed ID: 17509069
[TBL] [Abstract][Full Text] [Related]
11. Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus.
Baig MMFA; Khan S; Naeem MA; Khan GJ; Ansari MT
Biomed Pharmacother; 2018 Jan; 97():1250-1258. PubMed ID: 29145151
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
14. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
Croxtall JD; Keam SJ
Drugs; 2008; 68(16):2387-409. PubMed ID: 18973400
[TBL] [Abstract][Full Text] [Related]
15. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population.
Schweizer A; Dejager S; Foley JE; Couturier A; Ligueros-Saylan M; Kothny W
Diabetes Obes Metab; 2010 Jun; 12(6):485-94. PubMed ID: 20518804
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
17. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
Ahrén B; Foley JE; Bosi E
Diabetes Obes Metab; 2011 Mar; 13(3):193-203. PubMed ID: 21205107
[TBL] [Abstract][Full Text] [Related]
18. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
Refaat R; Sakr A; Salama M; El Sarha A
Drug Dev Res; 2016 Sep; 77(6):300-9. PubMed ID: 27520857
[TBL] [Abstract][Full Text] [Related]
19. Reply to the "Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations'", by Avogaro (Journal of Diabetes and Its Complications 25 [2011] 352-353).
Marfella R; Paolisso G
J Diabetes Complications; 2011; 25(6):405-6. PubMed ID: 21775165
[No Abstract] [Full Text] [Related]
20. Comments on the article "Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations" by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83).
Avogaro A
J Diabetes Complications; 2011; 25(5):352-3. PubMed ID: 21334926
[No Abstract] [Full Text] [Related]
[Next] [New Search]
